Opus Genetics, Inc. (NASDAQ: IRD)

Ocuphire Pharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders. The company operates under the stock symbol 'OPHR' and is situated in the healthcare industry.

Ocuphire's primary business activities revolve around the development of novel therapies for retinal and refractive eye disorders. The company's operations span across the United States and other countries, as it conducts clinical trials and partners with other companies for the development and commercialization of its products.

The company generates revenue through the development and commercialization of its product candidates, as well as through the licensing of its technology to other companies. Ocuphire's revenue streams are primarily driven by its two main products, APX3330 and Phentolamine Ophthalmic Solution 0.75% (PS).

APX3330 is a small-molecule inhibitor of Ref-1, a regulator of transcription factors such as HIF-1α and NF-κB. This product has the potential to be an early, non-invasive treatment for diabetic retinopathy (DR). On the other hand, PS is a once-daily eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. PS was approved by the FDA for the treatment of pharmacologically-induced mydriasis under the brand name RYZUMVI in September 2023.

Ocuphire's competitive advantage lies in its unique mechanism of action. APX3330, for instance, targets Ref-1, a regulator of transcription factors, which has the potential to reduce inflammation and angiogenesis in DR. This mechanism sets Ocuphire apart from its competitors, making it a promising treatment option for this disease.

The company's key partnerships include a license and collaboration agreement with Viatris, Inc. (formerly known as Mylan N.V.) to develop and commercialize PS. Under this agreement, Viatris has exclusive rights to develop and commercialize PS outside of the United States. Ocuphire has also partnered with FamyGen Life Sciences, Inc. (now known as Viatris, Inc.) to develop and commercialize PS. This partnership has the potential to expand Ocuphire's reach and increase its revenue.

Ocuphire's financial performance has been strong, with the company reporting revenue of $35 million in 2022, primarily from the licensing of its technology to Viatris. The company's net loss was $23 million in 2022, primarily due to the costs associated with the development of its product candidates.

In the future, Ocuphire plans to continue the development of its product candidates, including APX3330 and PS. The company is also exploring opportunities to expand its pipeline through in-licensing and acquisition of new product candidates.

The brand names and/or trade names of its products and services include APX3330 and PS, which are sold under the brand name RYZUMVI. These products are key to Ocuphire's operations and revenue generation, and the company continues to invest in their development and commercialization.